Video

The Aftermath of Hepatitis C Drugs on Specialty Spending

Author(s):

Davy James, Managing Editor

David Lassen, chief clinical officer at Prime Therapeutics, discusses how high cost hepatitis C drugs have impacted the entire specialty landscape.

David Lassen, chief clinical officer at Prime Therapeutics, discusses how high cost hepatitis C drugs have impacted the entire specialty landscape.

Related Videos
California Wildfires, Pharmacies, Community | image Credit: J Bettencourt/peopleimages.com | stock.adobe.com
California Wildfire, Pharmacy, Community | Image Credit: Erin | stock.adobe.com
Allergies, Asthma, Biologic Treatment, Pharmacists | Image Credit: Pixel-Shot | stock.adobe.com
Related Content
IV drip -- Image credit: sudok1 | stock.adobe.com
January 22nd 2025

Cost Avoidance and Satisfaction Associated With Clinical Pharmacy Services in a Veterans Affairs Specialty Clinic

Miranda Beaudoin Rampone, PharmD, MSCS, CSP Bryce A. Edwards, PharmD, RPh Allison Spaulding, PharmD Leslie Ochs, PharmD, PhD, BCPS
Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments
November 25th 2024

Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments

Drug Prices, Ozempic, Biktarvy | Image Credit: lucid_dream | stock.adobe.com
January 21st 2025

Ozempic, Biktarvy Among the Drugs Seeing List Price Increases at the Start of 2025

Ashley Gallagher, Editor
Pharmacy Focus: Oncology Edition- Exploring Pelareorep: A Novel Immunotherapy for Advanced Breast Cancer
October 28th 2024

Pharmacy Focus: Oncology Edition- Exploring Pelareorep: A Novel Immunotherapy for Advanced Breast Cancer

GLP-1, Diabetes, Type 2 Diabetes | Image Credit: © neirfy | stock.adobe.com
January 20th 2025

ASHP Midyear: Expert Discusses GLP-1 Medications and Incretin Mimetics for Diabetes Care

Ashley Gallagher, Editor
Medical model of chronic kidney disease -- Image credit: kanruthai | stock.adobe.com
January 20th 2025

Study Shows Potential Population-Level Benefits of Intensive BP Targets in Adults With CKD

Gillian McGovern, Associate Editor